Investors Hype Robotics While Biotech Suffers a Deep Funding Winter
zebird0 · x · 2026-08-14
A tech investor points out that software investors are suddenly highly enthusiastic about robotics, despite knowing very little about hardware.
In stark contrast, the biotech sector remains in a deep funding winter despite the massive success of GLP-1 drugs. The author questions why the capital markets treat these two sectors so differently, given that both have similarly tough capital costs and timelines.
Related event: Software VCs Flock to Robotics Amid Biotech Funding Winter(2 posts)→
More from Venture
- Three CoreWeave co-founders have sold $3.3B in shares since IPO amid credit worries — SumitGup · 2026-10-16
- Robotics data startups compared: Scale AI tops $1B revenue as 9 LLM vs robotics data suppliers benchmarked — FinanceYF5 · 2026-10-16
- Only 4.5% of US consumers pay for AI, but the top 1% of spenders drive 19.5% of revenue — dumpshoot · 2026-10-16
- Anthropic ARR growth cools to 6.5% MoM, but OpenAI plus Anthropic revenue still climbing steadily — FinanceYF5 · 2026-10-16
- Hot take: products built on LLM APIs aren't AI-native, just reselling someone else's loop — fkasummer · 2026-10-16
- Marc Andreessen quips Anthropic secondaries are on a 'Tesla Roadster pipeline' — beffjezos · 2026-10-16